Envestnet Asset Management Inc. Has $2.17 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Envestnet Asset Management Inc. raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 6.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 59,970 shares of the specialty pharmaceutical company’s stock after buying an additional 3,495 shares during the period. Envestnet Asset Management Inc. owned about 0.11% of Supernus Pharmaceuticals worth $2,169,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Supernus Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock valued at $222,411,000 after purchasing an additional 22,852 shares during the period. Geode Capital Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock valued at $54,633,000 after purchasing an additional 28,517 shares during the last quarter. American Century Companies Inc. increased its position in shares of Supernus Pharmaceuticals by 9.2% during the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock worth $41,248,000 after buying an additional 95,777 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Supernus Pharmaceuticals by 5.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock worth $27,242,000 after buying an additional 40,968 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Supernus Pharmaceuticals by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company’s stock valued at $14,449,000 after buying an additional 27,134 shares during the period.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 in the last 90 days. 9.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 17th.

Supernus Pharmaceuticals Trading Up 2.8 %

NASDAQ:SUPN opened at $32.22 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of 30.11 and a beta of 0.90. The firm has a fifty day simple moving average of $31.94 and a two-hundred day simple moving average of $34.99.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.